SCP Stock Overview
A biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Scope Fluidics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł157.60 |
| 52 Week High | zł239.00 |
| 52 Week Low | zł151.40 |
| Beta | -0.24 |
| 11 Month Change | -4.02% |
| 3 Month Change | -7.84% |
| 1 Year Change | -3.31% |
| 33 Year Change | 6.20% |
| 5 Year Change | 171.72% |
| Change since IPO | 765.93% |
Recent News & Updates
Shareholder Returns
| SCP | PL Medical Equipment | PL Market | |
|---|---|---|---|
| 7D | -3.9% | -6.1% | -3.1% |
| 1Y | -3.3% | -12.8% | -1.7% |
Return vs Industry: SCP exceeded the Polish Medical Equipment industry which returned -12.8% over the past year.
Return vs Market: SCP underperformed the Polish Market which returned -1.7% over the past year.
Price Volatility
| SCP volatility | |
|---|---|
| SCP Average Weekly Movement | 3.2% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: SCP has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: SCP's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 40 | Piotr Garstecki | www.scopefluidics.com |
Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.
Scope Fluidics S.A. Fundamentals Summary
| SCP fundamental statistics | |
|---|---|
| Market cap | zł427.97m |
| Earnings (TTM) | -zł26.67m |
| Revenue (TTM) | zł98.00k |
4,384x
P/S Ratio-16.1x
P/E RatioIs SCP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCP income statement (TTM) | |
|---|---|
| Revenue | zł98.00k |
| Cost of Revenue | zł2.07m |
| Gross Profit | -zł1.97m |
| Other Expenses | zł24.70m |
| Earnings | -zł26.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | -9.79 |
| Gross Margin | -2,014.29% |
| Net Profit Margin | -27,219.39% |
| Debt/Equity Ratio | 0% |
How did SCP perform over the long term?
See historical performance and comparison